Recruitment unclearEUCTR 2016-003435-38

A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

This historical record does not confirm current site availability.

Historical research recordMultiple countries

The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Who could participate?

This study is for people with schizophrenia. Other eligibility criteria apply.

Listed locations: Bulgaria · Croatia and 7 more locations
Compensation: Payment and expense reimbursement have not been verified.

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Recruitment unclear
Enrollment listed in the registry: 550
Sponsor: ACADIA Pharmaceuticals Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Bulgaria, Croatia, Czechia, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2016-003435-38
Official title: Show the full official title
A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Need help understanding this study?

Leave your email and we’ll get in touch to discuss your questions and possible next steps.

Recruitment & locations

Status unknown

Bulgaria · Croatia · Czechia

6 more locations

Germany
Hungary
Italy
Lithuania
Poland
Spain

Registry details

Historical country statuses

Bulgaria — Prematurely Ended
Czechia — Completed
Germany — Prematurely Ended
Spain — Ongoing
Croatia — Completed
Hungary — Prematurely Ended
Italy — Prematurely Ended
Lithuania — Completed
Poland — Prematurely Ended

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is ACADIA Pharmaceuticals Inc.

Who can participate?

This study is for people with schizophrenia. Other eligibility criteria apply.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me